Therapy Areas: Respiratory
Preclinical Results of Onxeo DNA Repair Inhibitor Show Strong Synergy, Prevention of PARPi Resistance
17 July 2018 - - Paris, France-based biotechnology company Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596) has released new positive results from preclinical studies of AsiDNA, its first-in-class DNA repair inhibitor, in combination with PARP inhibitors (PARPi), the company said.
AsiDNA is a first-in-class DNA repair inhibitor in the field of DNA damage response that mimics double-stranded DNA breaks in tumor cells, activating repair pathways, diverting repair enzymes from the target and finally depleting the cell through a unique mechanism of agonist and decoy.
The results point to the ability of AsiDNA to prevent the occurrence of resistance and to reverse the acquired resistance of the tumor cell after PARPi treatments.
They also show that the combination has a strong synergistic anti-tumor activity in in vitro and in vivo models of solid tumors resistant to PARPi (HR proficient).
Data of in vitro models of HR proficient triple negative breast cancer (TNBC) and small cell lung cancer show that AsiDNA maintains PARP1 expression, the repair enzyme inhibited by PARP inhibitors, and abrogates the occurrence of resistance to PARPi, including in models of cancers resistant to PARPi.
Combination treatment of olaparib with AsiDNA more than doubles the complete response rate observed with olaparib alone (71% vs. 33%) in an in vivo model of HR proficient TNBC model and inhibits tumor growth in a humanized patient-derived xenograft mice model of ovarian cancer resistant to olaparib.
Onxeo specializes in the development of innovative oncology drugs based on DNA-targeting and epigenetics.
The company is focused on bringing early-stage first-in-class or disruptive compounds (proprietary, acquired or in-licensed) from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.
Login
Username:

Password: